Bristol Myers Squibb (BMY) Goodwill & Intangibles (2009 - 2026)
Bristol Myers Squibb's (BMY) quarterly Goodwill & Intangibles came in at $39.1 billion in Q2 2026, down 9.33% year-over-year from $43.2 billion in Q2 2025, and down 2.14% quarter-over-quarter from $40.0 billion in Q1 2026.
Analysis
Bristol Myers Squibb (BMY) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Goodwill & Intangibles for 18 consecutive years, with $39.1 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Goodwill & Intangibles fell 9.33% year-over-year to $39.1 billion in Q2 2026; TTM through Jun 2026 was $39.1 billion, a 9.33% decrease from a year earlier, with the FY2025 full-year figure at $40.9 billion, down 9.26% from the prior year.
- Goodwill & Intangibles was $39.1 billion for Q2 2026 at Bristol Myers Squibb, down from $40.0 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $60.6 billion in Q1 2022 and troughed at $39.1 billion in Q2 2026.
- A 5-year average of $49.4 billion and a median of $49.4 billion in 2023 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles fell 0.43% in 2024 and declined 18.85% in 2025, its largest moves.
- Over 5 years, Goodwill & Intangibles stood at $57.0 billion in 2022, then fell by 15.38% to $48.2 billion in 2023, then decreased by 6.66% to $45.0 billion in 2024, then decreased by 9.26% to $40.9 billion in 2025, then dropped by 4.23% to $39.1 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $39.1 billion (Q2 2026), $40.0 billion (Q1 2026), and $40.9 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.13 Bn |
| Mar 31, 2026 | 39.98 Bn |
| Dec 31, 2025 | 40.86 Bn |
| Sep 30, 2025 | 42.21 Bn |
| Jun 30, 2025 | 43.15 Bn |
| Mar 31, 2025 | 44.22 Bn |
| Dec 31, 2024 | 45.03 Bn |
| Sep 30, 2024 | 48.72 Bn |
| Jun 30, 2024 | 51.16 Bn |
| Mar 31, 2024 | 54.50 Bn |
| Dec 31, 2023 | 48.24 Bn |
| Sep 30, 2023 | 50.10 Bn |
| Jun 30, 2023 | 52.47 Bn |
| Mar 31, 2023 | 54.73 Bn |
| Dec 31, 2022 | 57.01 Bn |
| Sep 30, 2022 | 59.29 Bn |
| Jun 30, 2022 | 58.14 Bn |
| Mar 31, 2022 | 60.60 Bn |
| Dec 31, 2021 | 63.03 Bn |
| Sep 30, 2021 | 65.45 Bn |